Journal for ImmunoTherapy of Cancer

The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy—from basic research to clinical application.

Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for the Journal for ImmunoTherapy of Cancer, an outlet devoted to and created by today's leaders in the field.

Read the Journal

Indexing

JITC is indexed in six major indexing sources, including PubMed, PubMed Central, MEDLINE, the Directory of Open Access journals, Scopus, and Thomson Reuters’ Emerging Sources Citation Index (ESCI). The ESCI is part of the robust Web and Science collection, the world’s largest compilation of research data, books, journals, proceedings, publications, and patents.

Free Publication

As a way to say thank you to the dedicated society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, SITC is pleased to offer society members waived article processing charges for manuscripts accepted through 2017. To take advantage of this member benefit, contact SITC at +1 414-271-2456 or info@sitcancer.org for your member code.

icon-jitc.png

Highly Accessed Articles

What is the article Altmetric Attention Score?

Altmetric_Score_donut.pngIndicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm, and represents a weighted count of the amount of attention picked up for a research output. Learn more here.

Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen

Gilda G. Hillman, Lyndsey A. Reich, Shoshana E. Rothstein, Lisa M. Abernathy, Matthew D. Fountain, Kali Hankerd, Christopher K. Yunker, Joseph T. Rakowski, Eric Quemeneur and Philippe Slos

Radio_Mouse_jitc.gif

We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune response to MUC1 tumor antigen, we have tested the efficacy of tumor irradiation combined with an MVA-MUC1-IL2 cancer vaccine (Transgene TG4010) for murine renal adenocarcinoma (Renca) cells transfected with MUC1...

Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer

Juan R. Cubillos-Ruiz, Eslam Mohamed and Paulo C. Rodriguez

Established tumors build a stressful and hostile microenvironment that blocks the development of protective innate and adaptive immune responses. Different subsets of immunoregulatory myeloid populations, including dendritic cells, myeloid-derived suppressor cells (MDSCs) and macrophages, accumulate in the stressed tumor milieu and represent a major impediment to the success of various forms of cancer immunotherapy. Specific conditions and factors within tumor masses, including hypoxia, nutrient starvation, low pH, and increased levels of free radicals, provoke a state of “endoplasmic reticulum (ER) stress” in both malignant cells and infiltrating myeloid cells...

Unfolding_jitc.gif

Open Forum Discussions

Log in to see this information

Either the content you're seeking doesn't exist or it requires proper authentication before viewing.

Recent JITC Articles